Plus Therapeutics, Inc.
PSTV
$0.7691
-$0.075-8.89%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.41M | 1.46M | 1.28M | 1.68M | 1.31M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.41M | 1.46M | 1.28M | 1.68M | 1.31M |
| Cost of Revenue | 2.19M | 2.86M | 2.77M | 2.76M | 2.79M |
| Gross Profit | -774.00K | -1.40M | -1.49M | -1.09M | -1.48M |
| SG&A Expenses | 3.13M | 2.40M | 2.20M | 2.21M | 2.38M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.31M | 5.26M | 4.98M | 4.98M | 5.17M |
| Operating Income | -3.90M | -3.80M | -3.70M | -3.30M | -3.86M |
| Income Before Tax | -3.90M | -2.87M | -2.94M | -3.26M | -3.81M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.90M | -2.87M | -2.94M | -3.26M | -3.81M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.90M | -2.87M | -2.94M | -3.26M | -3.81M |
| EBIT | -3.90M | -3.80M | -3.70M | -3.30M | -3.86M |
| EBITDA | -3.70M | -3.60M | -3.53M | -3.14M | -3.71M |
| EPS Basic | -0.50 | -0.37 | -0.45 | -0.75 | -0.85 |
| Normalized Basic EPS | -0.31 | -0.23 | -0.28 | -0.47 | -0.53 |
| EPS Diluted | -0.50 | -0.37 | -0.71 | -0.75 | -0.85 |
| Normalized Diluted EPS | -0.31 | -0.23 | -0.17 | -0.47 | -0.53 |
| Average Basic Shares Outstanding | 7.86M | 7.86M | 6.50M | 4.32M | 4.50M |
| Average Diluted Shares Outstanding | 7.86M | 7.86M | 10.74M | 4.32M | 4.50M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |